Literature DB >> 16002577

Bone morphogenetic protein receptor type II C-terminus interacts with c-Src: implication for a role in pulmonary arterial hypertension.

Wai K P Wong1, James A Knowles, Jane H Morse.   

Abstract

Mutations of bone morphogenetic protein receptor type II (BMPR-II) have been associated with familial and idiopathic pulmonary arterial hypertension (PAH). BMPR-II is a member of the transforming growth factor-beta receptor superfamily. It consists of extracellular, transmembrane, and kinase domains, and a unique C-terminus with mostly unknown function. However, a number of PAH-causing mutations are predicted to truncate the C-terminus, suggesting that this domain plays an important role in the homeostasis of pulmonary vessels. In this study, we sought to elucidate the functional role of this C-terminus by seeking its interacting partners. Using yeast two-hybrid screening, we identified c-Src tyrosine kinase as a binding partner of this C-terminus. In vitro co-immunoprecipitation confirmed their interaction. Mutations truncating the C-terminus disrupted their interaction, while missense mutation within kinase domain reduced their interaction. In addition, BMPR-II and c-Src tyrosine kinase colocalized within intracellular aggregates when overexpressed in HEK293 cells. Moreover, mutations truncating the C-terminus disrupted their colocalization, whereas missense mutation within kinase domain had no effect on their colocalization. Furthermore, BMP ligand stimulation decreased c-Src-activating phosphorylation at Tyrosine 418 in pulmonary smooth muscle cells in both time- and concentration-dependent manners. Mutations that truncated the C-terminus abolished this response. Taken together, these results suggest a model in which proliferative effect of c-Src by vasoactive molecules is balanced by opposing effect of BMP signaling in basal state, and the loss of this balance due to BMPR2 mutations leads to increased c-Src activity and subsequently cell growth.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16002577      PMCID: PMC2715351          DOI: 10.1165/rcmb.2005-0103OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  42 in total

1.  Src autoinhibition: let us count the ways.

Authors:  S R Hubbard
Journal:  Nat Struct Biol       Date:  1999-08

2.  Pathogenesis of pulmonary arterial hypertension: the need for multiple hits.

Authors:  Jason X-J Yuan; Lewis J Rubin
Journal:  Circulation       Date:  2005-02-08       Impact factor: 29.690

3.  Attenuated K+ channel gene transcription in primary pulmonary hypertension.

Authors:  X J Yuan; J Wang; M Juhaszova; S P Gaine; L J Rubin
Journal:  Lancet       Date:  1998-03-07       Impact factor: 79.321

Review 4.  Primary pulmonary hypertension.

Authors:  L J Rubin
Journal:  N Engl J Med       Date:  1997-01-09       Impact factor: 91.245

5.  Transforming growth factor-beta receptor mutations and pulmonary arterial hypertension in childhood.

Authors:  Rachel E Harrison; Rolf Berger; Sheila G Haworth; Robert Tulloh; Christoph J Mache; Nicholas W Morrell; Micheala A Aldred; Richard C Trembath
Journal:  Circulation       Date:  2005-02-01       Impact factor: 29.690

6.  The 2.35 A crystal structure of the inactivated form of chicken Src: a dynamic molecule with multiple regulatory interactions.

Authors:  J C Williams; A Weijland; S Gonfloni; A Thompson; S A Courtneidge; G Superti-Furga; R K Wierenga
Journal:  J Mol Biol       Date:  1997-12-19       Impact factor: 5.469

7.  Involvement of EGF receptor and c-Src in the survival signals induced by TGF-beta1 in hepatocytes.

Authors:  Miguel M Murillo; Gaelle del Castillo; Aránzazu Sánchez; Margarita Fernández; Isabel Fabregat
Journal:  Oncogene       Date:  2005-06-30       Impact factor: 9.867

8.  Association of Src tyrosine kinase with a human potassium channel mediated by SH3 domain.

Authors:  T C Holmes; D A Fadool; R Ren; I B Levitan
Journal:  Science       Date:  1996-12-20       Impact factor: 47.728

9.  Cloning and characterization of a human type II receptor for bone morphogenetic proteins.

Authors:  B L Rosenzweig; T Imamura; T Okadome; G N Cox; H Yamashita; P ten Dijke; C H Heldin; K Miyazono
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

10.  Identification of a human type II receptor for bone morphogenetic protein-4 that forms differential heteromeric complexes with bone morphogenetic protein type I receptors.

Authors:  T Nohno; T Ishikawa; T Saito; K Hosokawa; S Noji; D H Wolsing; J S Rosenbaum
Journal:  J Biol Chem       Date:  1995-09-22       Impact factor: 5.157

View more
  46 in total

Review 1.  Targeting non-malignant disorders with tyrosine kinase inhibitors.

Authors:  Friedrich Grimminger; Ralph T Schermuly; Hossein A Ghofrani
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

2.  Raf/ERK drives the proliferative and invasive phenotype of BMPR2-silenced pulmonary artery endothelial cells.

Authors:  Keytam S Awad; Jason M Elinoff; Shuibang Wang; Salina Gairhe; Gabriela A Ferreyra; Rongman Cai; Junfeng Sun; Michael A Solomon; Robert L Danner
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-11-20       Impact factor: 5.464

Review 3.  Bone Morphogenetic Protein functions as a context-dependent angiogenic cue in vertebrates.

Authors:  David M Wiley; Suk-Won Jin
Journal:  Semin Cell Dev Biol       Date:  2011-10-12       Impact factor: 7.727

4.  Connectivity map analysis of nonsense-mediated decay-positive BMPR2-related hereditary pulmonary arterial hypertension provides insights into disease penetrance.

Authors:  Charles Flynn; Siyuan Zheng; Ling Yan; Lora Hedges; Bethany Womack; Josh Fessel; Joy Cogan; Eric Austin; James Loyd; James West; Zhongming Zhao; Rizwan Hamid
Journal:  Am J Respir Cell Mol Biol       Date:  2012-02-03       Impact factor: 6.914

5.  Cadherin-6B stimulates an epithelial mesenchymal transition and the delamination of cells from the neural ectoderm via LIMK/cofilin mediated non-canonical BMP receptor signaling.

Authors:  Ki-Sook Park; Barry M Gumbiner
Journal:  Dev Biol       Date:  2012-04-19       Impact factor: 3.582

Review 6.  Epigenetics: novel mechanism of pulmonary hypertension.

Authors:  Jing-bin Huang; Jian Liang; Xiao-fang Zhao; Wen-sen Wu; Fu Zhang
Journal:  Lung       Date:  2013-09-20       Impact factor: 2.584

7.  Neprilysin regulates pulmonary artery smooth muscle cell phenotype through a platelet-derived growth factor receptor-dependent mechanism.

Authors:  Vijaya Karoor; Masahiko Oka; Sandra J Walchak; Louis B Hersh; York E Miller; Edward C Dempsey
Journal:  Hypertension       Date:  2013-02-04       Impact factor: 10.190

Review 8.  Kinase mutations in human disease: interpreting genotype-phenotype relationships.

Authors:  Piya Lahiry; Ali Torkamani; Nicholas J Schork; Robert A Hegele
Journal:  Nat Rev Genet       Date:  2010-01       Impact factor: 53.242

Review 9.  Pathogenic mechanisms of pulmonary arterial hypertension.

Authors:  Stephen Y Chan; Joseph Loscalzo
Journal:  J Mol Cell Cardiol       Date:  2007-09-20       Impact factor: 5.000

10.  The effect of rhBMP-2 on pulmonary arterioles remodeling in endotoxin-induced acute lung injury in rats.

Authors:  Kunpeng Wang; Jian Gong; Ling Pei; Shimin Shan; Wenfei Tan
Journal:  Clin Exp Med       Date:  2012-06-29       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.